Can CBD Make THC Stronger? New Research Raises Questions

CBD is commonly described as the calmer counterpart to THC. That reputation has helped make balanced cannabis products appealing to consumers who want a more controlled experience, and it has influenced public health advice encouraging products with higher CBD-to-THC ratios. Yet a new systematic review¹ and meta-analysis suggests that the relationship between these two cannabinoids is not as simple as one molecule cancelling out the other.

Researchers found that adding CBD to a fixed dose of THC can increase the body’s overall exposure to THC and produce a much larger increase in 11-hydroxy-THC, or 11-OH-THC. This active metabolite is created when the body processes THC and may be as potent as THC itself, or potentially more potent. It is especially relevant to swallowed products such as edibles, oils, capsules, and beverages.

The findings do not prove that CBD always intensifies a cannabis high. They do show that CBD can alter how THC is processed, making product effects harder to predict from cannabinoid ratios alone.

What Happens When CBD And THC Are Consumed Together?

The study, published in Neuroscience and Biobehavioral Reviews, combined evidence from 14 acute dosing studies involving 341 adults. Twelve used crossover designs, meaning participants received multiple study conditions at different times, while two used parallel groups. Seven studies administered cannabinoids orally, five used inhalation, one used intravenous dosing, and one combined intravenous THC with oral CBD.

Each included trial compared a fixed dose of THC on its own with the same THC dose administered alongside CBD. This design allowed the researchers to examine whether CBD changed the concentration of THC or 11-OH-THC circulating in the blood.

They focused on three pharmacokinetic measurements:

• Cmax, the highest measured blood concentration
• AUCt, total exposure from dosing to the final blood sample
• AUCinf, estimated total exposure through complete elimination

These measurements describe what the body does with a drug. They do not directly measure how intoxicated, anxious, impaired, or relaxed a person feels. That distinction is essential when interpreting the results.

CBD Increased Overall THC Exposure

CBD did not significantly change the pooled peak concentration of THC. In other words, the highest measured THC level was not reliably greater when CBD was added. However, total THC exposure measured to the final sampling point was significantly higher.

The ratio-of-means analysis indicated that THC AUCt was 1.311 times as high with CBD co-administration, equivalent to an average increase of about 31%. This finding remained significant in a sensitivity analysis that removed results relying on certain estimates or imputations.

However, the researchers rated the certainty of the THC evidence as very low. Eight of the 11 studies contributing to the AUCt analysis had a high risk of bias, and results varied substantially between studies. There was also no clear relationship between CBD dose and its effect on THC exposure.

The practical interpretation is therefore measured. CBD may extend or increase overall exposure to THC, but the available research cannot establish a dependable rule for predicting the size of that effect in a particular product or person.

The Strongest Signal Involved 11-OH-THC

The more convincing result concerned 11-OH-THC. Unlike an inactive breakdown product, 11-OH-THC can activate cannabinoid receptors and contribute to psychoactive effects.

When CBD accompanied THC, the peak concentration of 11-OH-THC was approximately 47% higher on average. Its total measured exposure was almost double. Both findings were supported by medium-certainty evidence, making them more dependable than the result for THC exposure itself.

Dose also mattered. Meta-regression found that increasing CBD doses were associated with larger effects on both the peak and total exposure to 11-OH-THC. THC dose also influenced the effect on total 11-OH-THC exposure. The three oral studies using the largest CBD doses, 105 mg, 450 mg, and 640 mg, recorded the largest CBD-related increases in this metabolite.

How CBD May Change THC Metabolism

The interaction may be partly explained by liver enzymes. THC is primarily converted into 11-OH-THC through the enzymes CYP2C9 and CYP2C19. The body then uses CYP2C9 to help convert 11-OH-THC into the inactive metabolite THC-COOH.

CBD can inhibit CYP2C9 and CYP2C19. As a result, adding a sufficiently large dose of CBD could change multiple stages of THC metabolism. It may alter the production of 11-OH-THC while also slowing its conversion into an inactive compound. The final outcome can depend on dose, timing, formulation, food intake, administration route, individual biology, and previous cannabis exposure.

This helps explain why the effects of combined cannabinoid products can appear contradictory. CBD may influence cannabinoid receptors in ways that differ from THC, while simultaneously increasing exposure to THC or its active metabolite through a pharmacokinetic interaction. These mechanisms could operate at the same time rather than producing a simple balancing effect.

Why Edibles Deserve Particular Attention

The meta-analysis did not establish that oral administration always produces a larger CBD interaction than inhalation. CBD doses were generally much higher in the oral studies, making it difficult to separate the effect of dose from the effect of administration route.

Still, there are sound reasons to pay special attention to ingestible products. Swallowed THC passes through the liver before reaching systemic circulation, producing considerably more 11-OH-THC than inhaled cannabis. Oral products can also contain far more CBD than a person could comfortably inhale. Inhaled CBD at high doses can cause coughing and throat irritation, which may change how much product is actually absorbed.

Edibles also have a delayed onset. A consumer who expects CBD to make a product inherently mild may take an additional serving before the first has reached full effect. If the CBD simultaneously increases exposure to 11-OH-THC, that assumption could contribute to an unexpectedly intense or prolonged experience.

What The Findings Mean For Cannabis Consumers

The study does not overturn lower-risk guidance suggesting that consumers choose products with less THC. Nor does it establish that every balanced product is more intoxicating than THC alone. Most commercially available products also contain cannabinoid doses and ratios that differ from those used in the highest-dose experiments.

What the research challenges is the idea that a CBD-to-THC ratio can function as a universal measure of gentleness. A product with more CBD may have different receptor-level effects, yet the CBD may also alter how the body processes THC. The ratio printed on a label therefore cannot fully predict onset, intensity, duration, impairment, or adverse effects.

Consumers can respond by treating THC dose as the primary variable rather than assuming CBD will neutralize it. This is particularly important for people with limited tolerance, those using oral products, and anyone who must avoid impairment. Prescribers should also consider the interaction when recommending cannabinoid medicines containing both compounds, especially at high CBD doses.

What The Research Still Cannot Tell Us

The review found substantial differences between studies. Participant experience with cannabis varied, as did sex distribution, cannabinoid formulations, dosing schedules, food conditions, blood sampling schedules, and study quality. Many trials were small, and several dose ranges between 30 mg and 400 mg of CBD were poorly represented.

All included studies examined acute dosing. That leaves an important gap for people who take CBD daily. Drug interaction research often administers the interacting compound repeatedly until its blood concentration reaches a steady state before introducing the second drug. Similar trials could reveal whether regular CBD use changes the metabolism of an occasional THC dose differently.

Future studies also need to connect pharmacokinetics with pharmacodynamics more directly. Measuring blood concentrations alongside intoxication, anxiety, cognition, driving performance, heart rate, and duration of effects would clarify whether higher 11-OH-THC exposure consistently translates into meaningful behavioural changes.

CBD And THC Require More Nuanced Guidance

CBD and THC are not simply opposing forces. Their interaction can occur at cannabinoid receptors, through liver metabolism, and across formulations with very different absorption patterns. The new meta-analysis provides the clearest combined evidence yet that CBD can increase overall THC exposure and, more consistently, raise concentrations of active 11-OH-THC.

That does not make CBD inherently unsafe or prove that it always intensifies intoxication. It does mean that higher CBD content should not be treated as a guarantee of a milder experience. For consumers, clinicians, producers, and regulators, the more accurate message is that cannabinoid dose, route, formulation, and metabolism matter alongside the ratio on the label.

References:

^{1. Chester, L. A., Sharafi, H., Mahroug, A., Ziegler, D., Hébert, F.-O., & Jutras-Aswad, D. (2026). Does co-administration of cannabidiol (CBD) influence the plasma availability of delta-9-tetrahydrocannabinol (THC) and its active metabolite in humans? A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 190, 106910. https://doi.org/10.1016/j.neubiorev.2026.106910}